

Evonik Financials & ESG KPIs

Financial KPI Group	P. 2
ESG KPI Group	P. 3
Division KPI	P. 4-8
Group Income Statement	P. 9-10
Group Balance Sheet	P. 11
Group Cash Flow Statement	P. 12
Group Net Financial Position	P. 13
Definitions	P. 14

As of Q3 2023 (published November 7, 2023)

Evonik Group Financials

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
External Sales	13,267	13,108	12,199	14,955	4,498	4,772	4,878	4,340	18,488	4,005	3,886	3,771
Growth (%)	4%	-1%	-7%	23%	34%	31%	26%	6%	24%	-11%	-19%	-23%
Volumes (%)	1%	-1%	-3%	11%	4%	-2%	-7%	-11%	-4%	-14%	-9%	-5%
Prices (%)	5%	-2%	-3%	12%	22%	24%	17%	11%	18%	3%	-5%	-6%
Exchange Rates (%)	-3%	1%	-2%	-2%	4%	5%	7%	3%	5%	1%	-2%	-4%
Other (incl. M&A; %)	1%	1%	1%	2%	4%	4%	9%	3%	5%	-1%	-3%	-8%
Adjusted EBITDA	2,150	2,153	1,906	2,383	735	728	615	413	2,490	409	450	485
Margin (%)	16.2%	16.4%	15.6%	15.9%	16.3%	15.3%	12.6%	9.5%	13.5%	10.2%	11.6%	12.9%
EBIT	1,049	1,086	819	1,173	456	421	326	-260	942	83	-255	-101
Adjusted EBIT	1,361	1,201	890	1,338	472	456	342	80	1,350	130	157	202
Margin (%)	10.3%	9.2%	7.3%	8.9%	10.5%	9.6%	7.0%	1.8%	7.3%	3.2%	4.0%	5.4%
Adjusted EPS	2.18	1.94	1.37	2.12	0.76	0.75	0.54	0.20	2.26	0.25	0.26	0.41
Free Cash Flow ¹	526	717	780	950	133	-239	288	603	785	21	-203	469
Cash Conversion Rate ²	24%	33%	41%	40%					32%			
Capex (Cash outflow for investment in intangible assets, pp&e)	948	880	956	865	176	165	229	295	865	206	237	162
Capital employed (annual average)	13,299	14,035	14,600	14,799					16,192			
ROCE (%)	10.2%	8.6%	6.1%	9.0%					8.3%			
Dividend (€)	1.15	1.15	1.15	1.17					1.17			
Employees (continuing operations)	32,623	32,423	33,106	33,004	33,151	33,235	33,836	34,029	34,029	33,918	33,357	33,575

¹ FY 2019: excl. extraordinary carve out taxes of -€245 m (MMA divestment) | ² Free cash flow conversion = FCF / adj. EBITDA

Evonik Group Environment, Social & Governance KPIs

	2018 FY	2019 FY	2020 FY	2021 FY	2022 FY
Strategy & Growth					
Sales share with "Next Generation Solutions"	>30%	35%	37%	41%	43%
Value added in € million	4,740	5,994	4,069	4,688	4,609
Governance & Compliance					
Training rate fighting money laundering			82%	96%	97%
Training rate antitrust law	74%	82%	88%	83%	85%
Training rate fighting corruption	83%	91%	88%	92%	91%
Training rate code of conduct	77%	89%	89%	89%	89%
Internal investigations	90	113	130	136	142
Disciplinary measures	106	60	110	152	168
Value Chain & Products					
Procurement volume (in € billion)	9.9	9.4	8.0	10.4	13.6
Production output (million metric tons)	11.03	9.16	8.93	9.54	8.81
Use of renewable raw materials in production	9.7%	7.9%	8.5%	9.7%	11.1%
Raw material suppliers covered by TfS assessments		66%	73%	69%	66%
No. of sustainability audits (Evonik/TfS)	380	335	289	300	389
No. of sustainability assessments (Evonik/TfS)	1,621	1,160	1,334	1,521	1,653
R&D expenses (€ million)	459	428	433	464	461
The environment					
Scope 1 greenhouse gas emissions (thousands metric tons CO ₂)	5,689	4,923	4,860	4,381 ^a	4,051 ^a
Scope 2 greenhouse gas emissions (thousands metric tons CO ₂)	882	563	571 ^b	1,916 ^a	1,853 ^a
Scope 3 greenhouse gas emissions (million metric tons CO ₂)	21.0	17.8	20.0 ^b	23.4	21.7
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO ₂) vs 2008	-31	-42	-43	-43	-6 ^c
Total water intake (in million m ³)	490.2	523.6	561.4	462 ^d	446 ^d
Specific water intake (in m ³ freshwater / metric ton production)	31.8	32.4	36.5	26.8 ^d	28.3 ^d
Production waste (thousand metric tons)	393	325	311	342 ^d	323 ^d
Specific production waste (in ton of waster per metric ton production)				0.036	0.037
Employees					
Early employee turnover	0.9%	0.9%	1.3%	2.2%	1.9%
Continuing professional development per employee (hours)	16	8	12	5	4
Women at level "Executives" (circle 1)	12.3%	11.2%	15.9%	17.7%	20.3%
Women at level "Senior management" (circle 2)	11.1%	12.6%	14.2%	17.6%	17.1%
Women in management (circle 3)	25.6%	26.4%	27.1%	28.7%	29.9%
Women in management (circles 1-3)	24.3%	25.2%	26.1%	27.9%	29.1%
Safety					
Occupational health performance index	5.5	5.5	5.4	5.4	5.5
Accident frequency rate (no. of accidents / working hours) ^b	0.17	0.24	0.16	0.19	0.25
Incident frequency rate (no. of accidents / working hours) ^b	1.08	1.10	1.45	0.48	0.49

a: adjusted figures corresponding to GHG Protocol Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Sales	3,380	3,381	3,225	3,710	1,049	1,116	1,113	906	4,184	921	906	882
<i>Growth (%)</i>	4%	0%	-5%	15%	16%	21%	19%	-4%	13%	-12%	-19%	-21%
<i>Volumes (%)</i>	3%	-1%	-3%	11%	-2%	-2%	-6%	-19%	-8%	-15%	-15%	-11%
<i>Prices (%)</i>	3%	1%	0%	5%	14%	18%	18%	11%	16%	5%	1%	-3%
<i>Exchange Rates (%)</i>	-2%	0%	-2%	-1%	3%	5%	6%	3%	4%	0%	-2%	-5%
<i>Other (incl. M&A; %)</i>	0%	0%	0%	0%	0%	0%	1%	1%	1%	-2%	-3%	-2%
Adjusted EBITDA	908	886	857	920	252	263	243	188	946	168	199	173
<i>Margin (%)</i>	26.9%	26.2%	26.6%	24.8%	24.0%	23.6%	21.8%	20.8%	22.6%	18.2%	22.0%	19.6%
EBIT	n.a.	712	683	739	205	214	194	169	782	117	150	127
Adjusted EBIT	744	716	681	739	205	214	194	139	753	121	152	127
<i>Margin (%)</i>	22.0%	21.2%	21.1%	19.9%	19.5%	19.2%	17.4%	15.3%	18.0%	13.1%	16.8%	14.4%
Capital expenditures	75	108	93	94	18	22	28	38	106	26	28	29
Capital employed (annual average)	3,912	4,396	4,244	4,168					4,631			
ROCE (%)	19.0%	16.3%	16.0%	17.7%					16.3%			
Employees	n.a.	3,651	3,666	3,693	3,742	3,733	3,785	3,824	3,824	3,556	3,545	3,538

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Sales	3,036	2,922	2,992	3,557	1,038	1,027	1,062	1,111	4,237	886	893	924
<i>Growth (%)</i>	1%	-4%	2%	19%	33%	23%	14%	10%	19%	-15%	-13%	-13%
<i>Volumes (%)</i>	5%	1%	2%	10%	4%	-6%	-10%	-1%	-4%	-12%	3%	5%
<i>Prices (%)</i>	1%	-5%	4%	11%	24%	21%	14%	7%	16%	-2%	-11%	-10%
<i>Exchange Rates (%)</i>	-5%	0%	-4%	-2%	6%	8%	9%	4%	7%	0%	-3%	-7%
<i>Other (incl. M&A; %)</i>	0%	0%	0%	0%	0%	0%	1%	0%	0%	-1%	-2%	-1%
Sales Animal Nutrition	1,574	1,438	1,474	1,789	556	543	562	531	2,192	441	437	447
Sales Health & Care	1,462	1,484	1,518	1,768	481	484	500	580	2,045	445	457	477
Adjusted EBITDA	550	462	560	717	222	185	148	122	677	76	71	127
<i>Margin (%)</i>	18.1%	15.8%	18.7%	20.2%	21.4%	18.0%	13.9%	11.0%	16.0%	8.6%	8.0%	13.7%
EBIT	n.a.	207	285	404	150	119	83	44	396	17	-298	58
Adjusted EBIT	362	231	301	453	155	120	82	48	405	13	7	69
<i>Margin (%)</i>	11.9%	7.9%	10.1%	12.7%	14.9%	11.7%	7.7%	4.3%	9.6%	1.5%	0.8%	7.5%
Capital expenditures	442	214	139	164	25	42	64	112	243	59	106	79
Capital employed (annual average)	2,808	3,974	3,914	3,893					4,286			
ROCE (%)	12.9%	5.8%	7.7%	11.6%					9.4%			
Employees	n.a.	5,322	5,295	5,453	5,540	5,594	5,680	5,690	5,690	5,745	5,807	5,697

in € million	2018 FY ¹	2019 FY	2020 FY	2021 FY	2022 Q1 ²	2022 Q2 ²	2022 Q3 ²	2022 Q4 ²	2022 FY ²	2023 Q1	2023 Q2	2023 Q3
Sales	3,382	3,371	3,235	3,918	1,284	1,335	1,365	1,256	5,240	1,188	1,119	1,100
Growth (%)	7%	0%	-4%	21%	30%	27%	26%	12%	23%	-7%	-16%	-20%
Volumes (%)	-3%	-4%	-7%	16%	9%	4%	-1%	-8%	1%	-16%	-17%	-12%
Prices (%)	7%	3%	-1%	4%	16%	21%	20%	17%	18%	10%	3%	-4%
Exchange Rates (%)	-2%	0%	-2%	-2%	3%	3%	6%	3%	4%	0%	-2%	-4%
Other (incl. M&A; %)	5%	1%	6%	3%	2%	-1%	1%	0%	0%	-1%	0%	0%
Sales Inorganics	2,325	2,312	2,315	2,754	946	996	1,017	933	3,891	860	820	793
Sales Polymers	1,057	1,059	920	1,164	338	339	348	323	1,349	328	299	307
Adjusted EBITDA	631	651	529	650	212	219	188	124	743	164	122	135
Margin (%)	18.7%	19.3%	16.4%	16.6%	16.5%	16.4%	13.8%	9.9%	14.2%	13.8%	10.9%	12.3%
EBIT	n.a.	443	226	346	137	141	108	19	405	71	-51	-9
Adjusted EBIT	434	433	270	374	140	144	111	21	416	79	34	41
Margin (%)	12.8%	12.8%	8.3%	9.5%	10.9%	10.8%	8.1%	1.7%	7.9%	6.6%	3.0%	3.7%
Capital expenditures	243	303	466	379	45	61	69	91	266	46	51	50
Capital employed (annual average)	2,565	3,651	4,244	4,637					5,109			
ROCE (%)	16.9%	11.9%	6.4%	8.1%					8.1%			
Employees	n.a.	7,065	7,874	7,742	7,916	7,936	8,009	8,011	8,011	8,095	8,113	8,079

¹ First-time consolidation of acquired PeroxyChem business as of February 2020 (FY 2019 sales: ~USD300 m; adj. EBITDA: ~USD64 m); First-time consolidation of Porocel business as of November 2020 (FY 2019 sales: ~USD100 m; adj. EBITDA: ~USD23 m)

² Restated for the alkoxides business (€407 m in sales and €59 m in adj. EBITDA in FY 2022), which was moved from Performance Materials to Smart Materials as of January 1st, 2023; sales growth rates and price/volume analysis not restated

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1 ¹	2022 Q2 ¹	2022 Q3 ¹	2022 Q4 ¹	2022 FY ¹	2023 Q1	2023 Q2	2023 Q3
Sales	2,789	2,634	1,983	2,911	844	945	797	666	3,253	707	694	616
<i>Growth (%)</i>	7%	-6%	-25%	47%	63%	47%	15%	-9%	26%	-16%	-27%	-23%
<i>Volumes (%)</i>	-1%	0%	-8%	10%	6%	-7%	-16%	-22%	-11%	-14%	-6%	-4%
<i>Prices (%)</i>	9%	-7%	-17%	40%	51%	45%	23%	11%	30%	-4%	-17%	-9%
<i>Exchange Rates (%)</i>	-2%	1%	0%	-3%	6%	9%	8%	2%	7%	2%	0%	-3%
<i>Other (incl. M&A; %)</i>	1%	0%	0%	0%	1%	0%	0%	0%	0%	0%	-4%	-7%
Adjusted EBITDA	243	248	88	317	82	142	63	63	350	37	45	34
<i>Margin (%)</i>	8.7%	9.4%	4.4%	10.9%	9.7%	15.0%	7.9%	9.5%	10.8%	5.2%	6.5%	5.5%
EBIT	n.a.	101	-48	169	53	108	24	-348	-163	-4	5	-215
Adjusted EBIT	158	117	-45	188	53	111	31	31	225	8	9	12
<i>Margin (%)</i>	5.7%	4.4%	-2.3%	6.5%	6.3%	11.7%	3.9%	4.7%	6.9%	1.1%	1.3%	1.9%
Capital expenditures	57	55	49	63	12	11	16	23	60	11	10	5
Capital employed (annual average)	919	1,296	1,293	1,209					1,158			
ROCE (%)	17.2%	9.0%	-3.5%	15.6%					19.4%			
Employees	n.a.	1,645	1,798	1,964	1,885	1,908	1,941	1,951	1,951	2,240	1,641	1,732

¹ Restated for the alkoxides business (€407 m in sales and €59 m in adj. EBITDA in FY 2022), which was moved from Performance Materials to Smart Materials as of January 1st, 2023, sales growth rates and price/volume analysis not restated

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Sales	680	800	764	859	283	349	541	401	1,574	303	274	249
<i>Growth (%)</i>	-4%	18%	-4%	12%	55%	82%	146%	52%	83%	7%	-22%	-54%
Adjusted EBITDA	-182	-94	-128	-221	-33	-81	-27	-85	-226	-36	13	16
EBIT	n.a.	-377	-327	-485	-89	-161	-83	-145	-478	-118	-61	-62
Adjusted EBIT	-336	-296	-317	-416	-81	-133	-76	-159	-449	-91	-45	-47
Capital expenditures	151	162	248	229	37	25	44	75	181	39	32	34
Employees	n.a.	14,740	14,473	14,152	14,068	14,064	14,421	14,553	14,553	14,282	14,251	14,529

Group Income Statement

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Sales	13,267	13,108	12,199	14,955	4,498	4,772	4,878	4,340	18,488	4,005	3,886	3,771
Cost of sales	-9,271	-9,413	-8,865	-10,925	-3,277	-3,559	-3,784	-3,637	-14,257	-3,143	-3,392	-3,181
Gross profit on sales	3,996	3,695	3,334	4,030	1,221	1,213	1,094	703	4,231	862	494	590
Selling expenses	-1,563	-1,511	-1,501	-1,717	-492	-512	-540	-491	-2,035	-483	-471	-438
Research and development expenses	-437	-428	-433	-464	-112	-113	-115	-120	-460	-113	-107	-115
General administrative expenses	-599	-568	-531	-546	-130	-154	-129	-141	-554	-133	-125	-113
Other operating income & expenses	-358	-107	-65	-138	-33	-18	15	-216	-252	-52	-49	-26
Result from investments recognized at equity	10	5	15	8	2	5	1	4	12	2	3	1
Income before financial result and income taxes, continuing operations = EBIT	1,049	1,086	819	1,173	456	421	326	-260	942	83	-255	-101
Financial Result	-155	-132	-135	-88	-12	4	-21	9	-19	-14	-30	-13
Income before income taxes, continuing operations	894	954	684	1,085	444	425	305	-251	923	69	-285	-114
Income taxes	-186	-180	-181	-316	-126	-123	-90	-30	-369	-20	19	23
Income after taxes, continuing operations	708	774	503	769	318	302	215	-281	554	49	-266	-91
Income after taxes, discontinued operations	246	1,353	-24	-2	-	-	-	-	1	-	-	-
Income after taxes	954	2,127	479	767	318	302	215	-281	555	49	-266	-91
thereof attributable to non-controlling interests	22	21	14	21	4	5	1	3	15	2	4	5
Shareholders of EVONIK Industries AG (net income)	932	2,106	465	746	314	297	214	-284	540	47	-270	-96
EPS	2.00	4.52	1.00	1.60	0.67	0.64	0.46	-0.61	1.16	0.10	-0.58	-0.21

Group Adjusted Income Statement

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Sales	13,267	13,108	12,199	14,955	4,498	4,772	4,878	4,340	18,488	4,005	3,886	3,771
Adjusted EBITDA	2,150	2,153	1,906	2,383	735	728	615	413	2,490	409	450	485
Depreciation and amortization	-789	-952	-1,016	-1,045	-263	-272	-273	-333	-1,140	-279	-293	-283
Adjusted EBIT	1,361	1,201	890	1,338	472	456	342	80	1,350	130	157	202
Adjusted net financial result	-151	-185	-146	-97	-12	4	-21	10	-19	-12	-27	-13
Depreciation and amortization on intangible assets	143	136	149	162	41	41	39	48	169	41	39	38
Adjusted Income before income taxes, continuing operations	1,353	1,152	893	1,403	501	501	360	138	1,500	159	169	227
Adjusted income taxes, continuing operations	-317	-229	-239	-396	-141	-145	-106	-39	-431	-42	-42	-33
Adjusted income after taxes	1,036	923	654	1,007	360	356	254	99	1,069	117	127	194
Adjusted non-controlling interest	-22	-21	-14	-21	-4	-5	-1	-5	-15	-2	-4	-5
Adjusted net income	1,014	902	640	986	356	351	253	94	1,054	115	123	189
Adjusted EPS	2.18	1.94	1.37	2.12	0.76	0.75	0.54	0.20	2.26	0.25	0.26	0.41

Adjustments

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Restructuring	-204	-18	-14	-20	0	-23	-3	-89	-115	-34	-11	-1
Impairment losses/reversal of impairment losses	7	-47	4	-27	0	0	0	-334	-334	-7	-390	-47
Acquisition / divestment of shareholdings	-31	-30	-37	-13	-2	-3	-3	48	40	-6	-6	-235
Other	-84	-20	-24	-105	-14	-9	-10	34	1	0	-5	-20
= Adjustments	-312	-115	-71	-165	-16	-35	-16	-340	-408	-47	-412	-303

Group Balance Sheet

Assets

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 FY	2023 Q1	2023 Q2	2023 Q3
Intangible assets	6,134	5,858	5,877	6,045	6,063	6,204	6,332	5,710	5,613	5,585	5,609
Property, plant and equipment	6,785	6,435	6,588	6,963	6,974	7,071	7,239	6,962	6,893	6,269	6,276
Right of use assets (capitalized leasing)		640	668	608	616	748	896	972	967	974	984
Investments recognized at equity	46	45	75	81	79	82	83	88	89	82	82
Financial assets	233	625	607	581	568	451	403	441	319	385	425
Deferred tax assets	1,419		2,004	1,755	1,589	1,134	1,091	890	1,001	1,100	991
Other income tax assets	16		13	16	16	16	18	19	20	20	21
Other non-financial assets	56	82	102	125	119	112	79	64	61	69	74
Non-current assets	14,689	15,415	15,934	16,174	16,024	15,818	16,141	15,146	14,963	14,484	14,462
Inventories	2,304	1,884	1,806	2,548	2,863	3,279	3,450	2,820	3,093	2,919	2,716
Other income tax assets	180	325	211	199	157	156	151	98	98	102	140
Trade accounts receivable	1,686	1,569	1,455	1,954	2,345	2,482	2,327	1,898	2,046	1,848	1,802
Other non-financial assets	295	387	231	382	474	527	595	546	582	622	535
Financial assets	140	1,278	697	571	573	487	441	581	530	437	291
Cash and cash equivalents	988	1,165	563	456	647	731	1,078	645	634	398	588
Current assets	5,593	6,608	4,963	6,110	7,059	7,662	8,042	6,588	6,983	6,326	6,072
Assets held for sale	0	0	0	0	0	0	98	76	64	486	262
Current assets	5,593	6,608	4,963	6,110	7,059	7,662	8,140	6,664	7,047	6,812	6,334
Total assets	20,282	22,023	20,897	22,284	23,083	23,480	24,281	21,810	22,010	21,296	20,796

Liabilities

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 FY	2023 Q1	2023 Q2	2023 Q3
Issued capital	466	466	466	466	466	466	466	466	466	466	466
Reserves	7,263	8,504	7,546	8,823	9,712	10,671	11,247	10,508	10,265	9,317	9,653
Equity attributable to shareholders of Evonik Industries AG	7,729	8,970	8,012	9,289	10,178	11,137	11,713	10,974	10,731	9,783	10,119
Equity attributable to non-controlling interests	96	90	87	83	83	84	84	82	81	78	79
Total equity	7,825	9,060	8,099	9,372	10,261	11,221	11,797	11,056	10,812	9,861	10,198
Provisions for pensions and other post-employment benefits	3,732	3,967	4,618	3,766	3,166	1,780	1,655	1,359	1,547	1,624	1,189
Other provisions	855	779	715	657	631	639	628	542	526	513	508
Deferred tax liabilities	557	537	586	628	644	656	678	661	649	635	653
Other income tax liabilities	223	320	275	195	202	216	209	246	251	250	249
Financial liabilities	3,689	3,713	3,564	3,531	2,795	3,649	4,043	4,117	4,112	4,279	3,483
Other payables	47	93	114	143	141	132	164	182	138	147	146
Non-current liabilities	9,103	9,409	9,872	8,920	7,579	7,072	7,377	7,107	7,223	7,448	6,228
Other provisions	1,047	778	744	892	984	660	739	732	818	546	569
Other income tax liabilities	64	59	136	211	230	226	225	189	180	172	164
Financial liabilities	395	918	434	477	1,373	1,565	1,521	429	346	795	1,330
Trade accounts payable	1,493	1,324	1,273	2,022	2,139	2,173	2,013	1,735	1,925	1,659	1,531
Other payables	355	475	339	390	517	563	596	501	640	630	585
	3,354	3,554	2,926	3,992	5,243	5,187	5,094	3,586	3,909	3,802	4,179
Liabilities associated with assets held for sale	0	0	0	0	0	0	13	61	66	185	191
Current liabilities	3,354	3,554	2,926	3,992	5,243	5,187	5,107	3,647	3,975	3,987	4,370
Total equity and liabilities	20,282	22,023	20,897	22,284	23,083	23,480	24,281	21,810	22,010	21,296	20,796

Group Cash Flow Statement

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY	2023 Q1	2023 Q2	2023 Q3
Income before financial result and income taxes, continuing operations = EBIT	1,049	1,086	819	1,173	456	421	326	-260	942	83	-255	-101
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	787	984	1,018	1,073	264	274	275	755	1,568	311	675	574
Result from investments recognized at equity	-10	-5	-15	-8	-2	-4	-2	-4	-12	-2	-4	-1
Gains/losses on disposal of non current assets	3	-13	-10	43	1	2	0	-53	-50	-1	13	0
Change in inventories	-242	129	70	-675	-278	-336	-123	467	-270	-300	52	227
Change in trade accounts receivable	75	41	54	-449	-362	-100	192	312	42	-178	50	61
Change in trade accounts payable and current advance payments received from customers	15	-62	-30	680	150	15	-184	-238	-257	223	-127	-177
Change in provisions for pensions and other post-employment benefits	-229	-60	-14	83	21	9	-5	-44	-19	-5	-15	-31
Change in other provisions	158	-294	-133	207	66	-289	85	-11	-149	92	-263	31
Change in miscellaneous assets/liabilities	26	-15	33	-23	34	7	12	-44	10	53	-46	108
Cash inflows/outflows from interest	-	-	-	-	-	-	-	-	-	-	-	-
Cash inflows from dividends	12	15	27	19	11	4	0	4	19	11	5	0
Tax payments relating to carve-out of the methacrylates business	-	-245	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-170	-209	-83	-308	-52	-77	-59	14	-174	-60	-51	-60
Cash flow from operating activities, continuing operations	1,474	1,352	1,736	1,815	309	-74	517	898	1,650	227	34	631
Cash flow from operating activities, discontinued operations	286	-31	-9	0	0	0	0	0	0	0	0	0
Cash flow from operating activities	1,760	1,321	1,727	1,815	309	-74	517	898	1,650	227	34	631
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-948	-880	-956	-865	-176	-165	-229	-295	-865	-206	-237	-162
Cash outflows for investments in shareholdings	-39	-427	-474	-85	-11	-1	-6	-9	-27	-2	0	-11
Cash outflows for loss from divestments of shareholdings investment property	-	-	-	-145	-	-	4	93	97	-4	-22	-1
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	16	25	45	9	3	-	-	5	13	1	1	0
Cash inflows/outflows from divestments of businesses and other shareholdings	68	2,208	65	2	-	-	-	-	43	0	2	2
Cash inflows/outflows relating to securities, deposits and loans	-24	-1,223	720	23	-9	91	38	-123	-3	-21	120	149
Cash inflows from interest	43	52	30	12	3	4	5	4	16	10	10	6
Cash flow from investing activities, continuing operations	-884	-245	-570	-1,070	-190	-71	-188	-328	-777	-167	-141	-17
Cash flow from investing activities, discontinued operations	-89	-47	0	0	0	0	0	0	0	0	0	0
Cash flow from investing activities	-973	-292	-570	-1,070	-190	-71	-188	-328	-777	-167	-150	-17
Cash inflows/outflows relating to capital contributions	2	4	2	0	0	0	0	0	0	0	0	0
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	-536	-536	0	-545	0	0	-545	0	-545	0
Cash outflows for dividends to non-controlling interests	-16	-12	-16	-21	-2	-8	-1	-2	-13	-1	-3	-3
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	0	0	0	0	0	-5	0	-5	0	0	0
Cash outflows for the purchase of treasury shares	-17	-17	-16	-15	-16	0	0	0	-16	-16	0	0
Cash inflows from the sale of treasury shares	13	13	12	12	0	12	0	0	12	0	12	0
Cash inflows from the addition of financial liabilities	61	110	1,039	655	156	926	426	141	1,649	54	490	151
Cash outflows for repayment of financial liabilities	-192	-295	-2,156	-948	-60	-81	-331	-1,105	-1,577	-93	-56	-529
Cash inflows/outflows in connection with financial transactions	8	-1	14	91	1	-65	-39	-1	-104	3	7	6
Cash outflows for interest	-121	-114	-77	-94	-14	-9	-23	-27	-73	-15	-17	-51
Cash flow from financing activities, continuing operations	-798	-848	-1,734	-856	65	230	27	-994	-672	-68	-112	-426
Cash flow from financing activities, discontinued operations	-3	-8	0	0	0	0	0	0	0	0	0	0
Cash flow from financing activities	-801	-856	-1,734	-856	65	230	27	-994	-672	-68	-112	-426
Change in cash and cash equivalents	-14	173	-577	-111	184	85	356	-424	201	-8	-219	188
Cash and cash equivalents as of beginning of period	1,004	988	1,165	563	456	647	731	1,078	456	645	633	398
Change in cash and cash equivalents	-14	173	-577	-111	184	85	356	-424	201	-8	-219	188
Changes in exchange rates and other changes in cash and cash equivalents	-2	4	-25	4	7	-1	4	-22	-12	-3	-16	3
Cash and cash equivalents as of end of period	988	1,165	563	456	647	731	1,091	632	645	634	398	589
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	13	-13	0	0	0	1
Cash and cash equivalents as on the balance sheet as of end of period	988	1,165	563	456	647	731	1,078	645	645	634	398	588

Group Net Financial Position

in € million	2018 FY	2019 FY	2020 FY	2021 FY	2022 Q1	2022 Q2	2022 Q3	2022 FY	2023 Q1	2023 Q2	2023 Q3
Non-current financial liabilities	-3,683	-3,712	-3,564	-3,527	-2,776	-3,626	-4,001	-4,074	-4,064	-4,118	-3,335
Current financial liabilities	-230	-806	-368	-232	-1,106	-1,282	1,180	-243	-264	-711	-1,160
Financial debt	-3,913	-4,518	-3,932	-3,759	-3,882	-4,908	-5,181	-4,317	-4,328	-4,829	-4,495
- Cash and cash equivalents	988	1,165	563	456	647	731	1,078	645	634	398	588
- Current securities	8	1,203	466	446	441	341	296	413	434	313	165
- Other financial assets	10	9	17	0	0	0	0	2	2	2	2
Financial assets	1,006	2,377	1,046	902	1,088	1,072	1,374	1,060	1,070	713	755
Net financial debt/cash as stated on the balance sheet	-2,907	-2,141	-2,886	-2,857	-2,794	-3,836	-3,807	-3,257	-3,258	-4,116	-3,740
Net financial debt/cash, discontinued operations	-	-	-	-	-	-	-	-	-	-	-
Net financial debt/cash including discontinued operations	-2,907	-2,141	-2,886	-2,857	-2,794	-3,836	-3,807	-3,257	-3,258	-4,116	-3,740

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TIS Assessments	This number indicates how many raw material suppliers have been covered by TIS assessments in that year. The chemical industry set up the Together for Sustainability (TIS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
Specific water intake <small>in m3 freshwater per metric ton production</small>	Freshwater usage in relation to production.
Total water intake	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).